Skip to main content

View full-text article in PMC

. 2016 Mar 9;7(15):20773–20787. doi: 10.18632/oncotarget.8014

Table 2. Overlap of gene signatures with genes over-expressed in BTNBC and ER+ luminal-B breast cancers.

Signature	BTNBC				ER+ luminal-B
Signature	PDX (1127^a)	PDX FAP/CSPG4 low (793^a)	TCGA (1368^a)	TCGA low stroma (1763^a)	PDX (511^a)	PDX FAP/CSPG4 low (569^a)	TCGA (876^a)	TCGA low stroma (847^a)
Stromal (137^b)	20^*	14^*	2	9	1	5	4	6
CSC Up (90^c)	16^*	11^*	5	16^*	2	3	1	1
CSC Down (211^c)	14	12	13	18	15^*	14^*	27^*	29^*
EMT Up (144^d)	41^*	27^*	17	37^*	5	11^*	8	11
EM Down (156^d)	30^*	22^*	34^*	33^*	8	6	21^*	21^*
Reactive stroma (50)	11^*	8^*	0	6	0	0	1	1

^*

p < 0.05 by hyper-geometric test.

^a

Number of genes over-expressed in TNBC or ER+ luminal-B.

^b

From [10].

^c

Breast cancer stem cell (CSC) signature from [21].

^d

Epithelial-mesenchymal transition (EMT) signature from [20].

^e

From [22].